Company intelligence
Karmanos Cancer Institute
Karmanos cancer specialists will give you what you really want — Your Best Chance. #YourBestChance
About Karmanos Cancer Institute
Karmanos Cancer Institute is a leader in transformative cancer care, research and education through courage, commitment and compassion. The Karmanos vision is a world free of cancer. As part of McLaren Health Care, Karmanos is the largest provider of cancer care and research in Michigan. For more than 75 years, the administrative and research headquarters, along with the premier specialty cancer hospital, have been located in downtown Detroit. With multiple network sites, Karmanos delivers world-renowned care and access to clinical trials throughout Michigan and northern Ohio. The National Cancer Institute recognizes Karmanos as one of the best cancer centers in the nation with a comprehensive cancer center designation. Its academic partnership with the Wayne State University School of Medicine provides the framework for cancer research and education – defining new standards of care and improving survivorship. For more information, please call 1-800-KARMANOS (1-800-527-6266) or visit www.karmanos.org.
Verified activity
Signals from Karmanos Cancer Institute
5 published signals
Presence & Recognition
Karmanos Cancer Institute President and CEO Boris Pasche shared his journey from discovering the effects of radiofrequency waves on cancer cells to pioneering the FDA-approved TheraBionic P1 device in a recent episode of the Beyond the Chart podcast.
Reported by Karmanos Cancer Institute
Presence & Recognition
Karmanos Cancer Institute provides access to the latest clinical trials and advanced cellular therapies for hematology specialists.
Reported by Karmanos Cancer Institute
Presence & Recognition
Karmanos Cancer Institute hosted the Annual Gastrointestinal Cancer Symposium at the Barbara Ann Karmanos Cancer Institute and Wayne State University School of Medicine, featuring expert faculty from multiple institutions.
Reported by Karmanos Cancer Institute
Research & Knowledge
Karmanos Cancer Institute participated in the RASolute 302 Phase III clinical trial led by medical oncologist Najeeb Al Hallak, M.D., MS, serving as the leader.
Reported by Karmanos Cancer Institute
Legal & Regulatory
Karmanos Cancer Institute announced that the U.S. Food and Drug Administration approved daraxonrasib (RASONQUE, Revolution Medicines, Inc.) for eligible patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multi-agent systemic therapy.
Reported by Karmanos Cancer Institute